RARE DISEASERESEARCH ATLAS

ORPHA:451607

Cutaneous pseudolymphoma

low confidenceDisorder

Publications

777

Trials

0

Interventional, condition-specific

Researchers

949

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

A rare acquired skin disease characterized by a benign, etiologically variable lymphoproliferative process of the skin mimicking cutaneous lymphoma clinically and/or histologically, while not fulfilling criteria for the diagnosis of a specific disease. Depending on the predominant cell type in the infiltrate, T- and B-cell pseudolymphomas can be distinguished.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

lymphadenosis Benigna cutis · lymphocytoma cutis · pseudolymphoma of Spiegler

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    777 matched papers (282 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

777

777 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

777 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

282 in the last 10 years · low confidence

Phrase hits: 777 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

949

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Ariasi C4 papers · 2026

    Department of Dermatology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.

    Papers in Europe PMC
  2. 02
    Soglia S4 papers · 2026

    Department of Dermatology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.

    Papers in Europe PMC
  3. 03
    Damiani C3 papers · 2026

    University of Brescia

    Papers in Europe PMC
  4. 04
    Arisi M2 papers · 2026

    University of Brescia

    Papers in Europe PMC
  5. 05
    Battocchio S2 papers · 2024

    University of Brescia

    Papers in Europe PMC
  6. 06
    Behera B2 papers · 2025

    Department of Dermatology and Venereology, AIIMS, Bhubaneswar, Odisha, India.

    Papers in Europe PMC
  7. 07
    Bettolini L2 papers · 2024

    University of Brescia

    Papers in Europe PMC
  8. 08
    Bighetti S2 papers · 2024

    University of Brescia

    Papers in Europe PMC
  9. 09
    Bradamante M2 papers · 2019

    University Department of Dermatology and Venerology, University Hospital Centre Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia.

    Papers in Europe PMC
  10. 10
    Chaby G2 papers · 2020

    Dermatology Department, Amiens-Picardie University Medical Center, Amiens, France.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

low confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Cutaneous pseudolymphoma" OR "lymphadenosis Benigna cutis" OR "lymphocytoma cutis" OR "pseudolymphoma of Spiegler" OR "pseudolymphoma of the Spiegler"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Cutaneous pseudolymphoma" OR "lymphadenosis Benigna cutis" OR "lymphocytoma cutis" OR "pseudolymphoma of Spiegler" OR "pseudolymphoma of the Spiegler"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (777) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T16:39:37.583Z